Clinical Trial Finder

Hundreds of clinical trials are rolled out around the world monthly, and many of them are designed to specifically uncover and manage the medical needs of people with sickle cell disease and trait. We keep an updated list of these global studies here, so you don’t have to go searching for them. There might be active study recruitment and enrollment happening at a site near you. Explore the list below to see the different types of studies, and use the navigation options on the left to get as specific as you would like.

Filters
Sort by
A Multicentre Trial Evaluating the Efficacy and Safety of Oral Decitabine Tetrahydrouridine (NDec) in Patients With Sickle Cell Disease

This study examines how well a new, potential medicine called NDec works and is tolerated in people with sickle cell disease.

Locations

398 United States sites

155 India sites

125 United Kingdom sites

75 Canada sites

75 Italy sites

50 France sites

50 Spain sites

50 Turkey sites

49 Greece sites

25 South Africa sites

4 Switzerland sites

Age

> 18 Years

Phase

Phase 2

LEARN MORE
A Phase 3 Study to Evaluate the Safety and Efficacy of a Single Dose of CTX001 in Pediatric Subjects With Severe Sickle Cell Disease

This is a single-dose, open-label study in pediatric participants with severe SCD and hydroxyurea (HU) failure or intolerance.

Locations

60 United States sites

20 Italy sites

15 United Kingdom sites

4 Germany sites

Age

2 Years - 11 Years

Phase

Phase 3

LEARN MORE
Cutaneous Hydration Assessment in Sickle Cell Disease

This study will validate the diagnostic accuracy of a cutaneous hydration sensor.

Locations

23 United States sites

Age

> 12 Years

Phase

Not Applicable

LEARN MORE
A Phase 2 Open-Label Study to Evaluate Safety and Clinical Activity of Etavopivat in Patients With Thalassemia or Sickle Cell Disease

This clinical trial is a Phase 2 study that will evaluate the safety and clinical activity of etavopivat in patients with thalassemia or sickle cell disease and test how well etavopivat works to lower the number of red blood cell transfusions required and increase hemoglobin.

Locations

357 United States sites

55 Canada sites

32 Lebanon sites

Age

12 Years - 65 Years

Phase

Phase 2

LEARN MORE
A Phase 1/2 Study to Evaluate the Safety and Efficacy of a Single Dose of Autologous Clustered Regularly Interspaced Short Palindromic Repeats Gene-edited CD34+ Human Hematopoietic Stem and Progenitor Cells (EDIT-301) in Subjects With Severe Sickle Cell Disease

The purpose of this study is to evaluate the efficacy, safety and tolerability of treatment with EDIT-301 in adult participants with severe sickle cell disease (SCD).

Locations

424 United States sites

75 Canada sites

Age

18 Years - 50 Years

Phase

Phase 1/Phase 2

LEARN MORE
Sickle Cell Disease Treatment With Arginine Therapy (STArT) Trial

The trial of IV arginine therapy in children with Vaso-occlusive painful episodes (VOE) in sickle cell disease (SCD) is designed to further knowledge on efficacy and safety of the therapy.

Locations

240 United States sites

Age

3 Years - 21 Years

Phase

Phase 3

LEARN MORE
An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral Etavopivat, a Pyruvate Kinase Activator in Patients With Sickle Cell Disease (HIBISCUS)

This clinical trial is a Phase 2/3 study that will evaluate the efficacy and safety of etavopivat and test how well etavopivat works compared to placebo to improve the amount of hemoglobin in the blood and to reduce the number of vaso-occlusive crises (times when the blood vessels become blocked and cause pain).

Locations

1007 United States sites

133 United Kingdom sites

95 France sites

95 Spain sites

76 Greece sites

76 Italy sites

57 Canada sites

38 Lebanon sites

38 Germany sites

38 Oman sites

Age

12 Years - 65 Years

Phase

Phase 2/Phase 3

LEARN MORE
Designing an Implementation Strategy for Delivering Routine Mental Health Screening and Treatment for Adolescents and Adults With Sickle Cell Disease

African Americans living with chronic health conditions are more likely to experience depression and other mental health disorders than their healthy counterparts, and are more likely to experience severe depression than whites, but less likely to be diagnosed or receive treatment.

Locations

28 United States sites

Age

16 Years - 30 Years

Phase

Not Applicable

LEARN MORE
A 2-Part, Phase 1, Multi-Center, Single-Dose, Open Label, Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CSL889 in Adult Patients With Sickle Cell Disease

This is a phase 1, first-in-human, multi-center, open-label, single dose cohort study to evaluate the safety and tolerability, pharmacokinetics (PK), exploratory pharmacodynamics (PD), and biomarkers of target engagement of CSL889 following single intravenous (IV) doses in subjects with sickle cell disease (SCD).

Locations

152 United States sites

110 United Kingdom sites

44 Netherlands sites

Age

18 Years - 60 Years

Phase

Phase 1

LEARN MORE
An Open-label, Multi-center, Phase IV, Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study

This is a multi-center multi-national rollover study to allow continued access to crizanlizumab for patients with sickle cell disease (SCD) who are on crizanlizumab treatment in a Novartis-sponsored study (parent study) and are benefiting from the treatment as judged by the investigator.

Locations

134 United States sites

78 Belgium sites

78 Brazil sites

78 Turkey sites

52 France sites

52 Italy sites

52 Lebanon sites

26 Colombia sites

26 Oman sites

26 Germany sites

26 Spain sites

Age

> 6 Months Years

Phase

Phase 4

LEARN MORE